Concepta announces first myLotus® pregnancies
Concepta Plc (AIM: CPT), the innovative UK personalised healthcare company and developer of the proprietary self-test platform ("myLotus®") and suite of emerging test products targeting the mobile health market with a primary focus on women's fertility and hormone health announces today its first pregnancies and user testimonials for the myLotus® monitor and app.
myLotus® the revolutionary home based, self-test product was launched in the UK in November 2018 with early 'trying to conceive' users providing personal video feedback and testimonials on their menstrual cycle hormone changes and profile ('signatures') enabling women to better understand their menstrual cycle and fertility journey (www.mylotus.com). In March the Company announced its first supply agreement with Boots UK (part of Walgreens Boots Alliance).
User testimonials from pregnancy users included;
"MyLotus couldn't have been a better purchase if it tried. From the moment I came across it on instagram it just made so much sense to buy. Having been told it could possibly be a harder route for me to fall pregnant, I wanted something I could trust to help me and something which made total sense. MyLotus easily explains all the different features of how to use it, and the fact that it produces an individualised LH level for each ovulation test is quite frankly genius. This allowed me to track my ovulation in such a concise way that I felt in safe hands. The app is an added bonus which uses your data to inform you when you should be taking a pregnancy test and stores all your test results if you ever need to look back over or show your doctor. We fell pregnant within our first cycle of using MyLotus and I feel passionately that this was purely down to it. My average LH levels were quite low so only MyLotus would have been able to catch my spike using the numerical factor. The added bonus of MyLotus was the 9 pregnancy tests the pack comes with, which I happily used every single one to quadruple check I really was pregnant :)" Isabel. (London)
"Myself and my partner are in our late 30s and decided we wanted to start trying for children. We tried the normal vitamin supplements and over the counter ovulation tests but after 18 months had not conceived. As reasonably healthy people we knew age was a factor, so decided to try the lotus fertility monitor as a more specific aid for ovulation. It's an easy monitor to set up and use and importantly is very specific to you, your cycle and hormone levels and the support from customer care (in what can be an anxious time) is excellent, I could not rate it more highly. We liked that the monitor shows the exact level of LH in urine so you can tell exactly (I mean exactly) when your peak is. This is why it is miles above any other fertility aids. After just two months of using the monitor we had the lovely news that we are now expecting a baby. Good health management and the correct vitamins is very important, but I feel we can put our success down to lotus and their support. Please get a hold of one, and don't lose hope. Ever! With love to all the couples trying." Naomi. (Scotland)
myLotus® empowers women to self-test their personalised hormone levels and identify their optimal fertile days thereby improving their chances of naturally getting pregnant. myLotus® enables women to monitor their fertile phase as part of their menstrual cycle and is the only home test to 'quantitatively' measure hormone levels and the 'rate-of-change' of these levels preceding ovulation to help aid a natural conception. Users measure, record and track their hormone levels and follow their fertility journey in an accompanying free downloadable app available in iOS and Android formats via the www.mylotus.com website.
myLotus® is available to women who are planning to start a family or for those who have previously struggled to naturally conceive, enabling couples an alternative prior to considering more costly IVF treatment. The Company expects to release further hormone health and wellbeing tests to complement its fertility offering later this year.
Matthew Walls, Chairman said: "We are extremely proud and delighted for our first user pregnancies. We have waited patiently for our pregnancies to sufficiently progress before we released this sensitive and important news. We understand the difficulties and emotions involved in trying to conceive and look forward to supporting all our users on their pregnancy journey."
Matthew Walls, Chairman
Tel: +44 (0) 1234 866601
SPARK Advisory Partners Limited (Nomad)
Tel: +44 (0)20 368 3550
+44 (0) 20 7399 9400
About Concepta Plc:
Concepta Plc is an AIM-quoted pioneering UK healthcare company that has developed a proprietary product, myLotus®, targeted at the personalised mobile health market with a primary focus on hormone testing and increasing a woman's chances of naturally getting pregnant and to provide insight to unexplained infertility.
myLotus® is currently the only consumer product which allows both quantitative and qualitative home (self-test) test measurement of a woman's personal luteinizing hormone (LH) during ovulation and human chorionic gonadotropin (hCG) hormone level during pregnancy, facilitating higher conception rates and early diagnosis of fertility issues. The proposition of myLotus® is to empower women to better understand their hormone levels and menstrual cycle and help women conceive naturally by identifying their window of fertility and optimal time for conception.
The Company has received CE-mark certification for myLotus® and has launched its first product in the UK. The Company is preparing plans to roll-out across the core EU countries in 2019.
myLotus® is expected to be beneficial to users who have been unable to conceive after 6 months of trying. This highly motivated target group of women won't typically be offered medical intervention until after 12 months of unsuccessfully trying to conceive, with IVF not usually offered until after two years of trying to conceive. Research indicates couples start to take positive action ahead of this time typically with little medical support to help them do so.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.